Fulcrum Therapeutics is expected to report zero revenue and a consensus loss of $0.10 per share for Q3 2026, with the stock currently trading at $3.71 versus an average analyst price target of $8.20.
Investors are primarily focused on clinical updates for pociredir in sickle cell disease and the strategic integration of the recently announced Slate Medicines merger. This quarter is pivotal as the company pivots its pipeline following previous late-stage trial failures.
Sustaining a cash runway into 2028 remains the top priority for analysts assessing the biotech's long-term viability post-restructuring.